SCHEMBL17460558

SCHEMBL17460558

COC(=O)CCCc1ccc(OCC2=C(c3ccc(C4(C#N)CC4)cc3)CCCC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 20/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17460471 0.99 FFAR4 (0.83) FFAR4
SCHEMBL17460606 0.93 FFAR4 (0.76) FFAR4
SCHEMBL17460625 0.90 FFAR4 (1.00) FFAR4
SCHEMBL17460572 0.90 FFAR4 (1.00) FFAR4
SCHEMBL17460615 0.89 FFAR4 (0.84) FFAR4
SCHEMBL17460603 0.89 FFAR4 (0.66) FFAR4
SCHEMBL17460602 0.88 FFAR4 (0.66) FFAR4
SCHEMBL17460636 0.86 FFAR4 (0.82) FFAR4
SCHEMBL17460490 0.85 FFAR4 (0.89) FFAR4
SCHEMBL17460622 0.85 FFAR4 (0.80) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3172185-B1 SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF PIRAMAL ENTPR LTD (IN) 2020-03-04 EP disclosed
US-10273230-B2 Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof Piramal Enterprises Limited (IN) 2019-04-30 US disclosed
US-20170210731-A1 SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF Piramal Enterprises Limited (IN) 2017-07-27 US disclosed
EP-3172185-A2 SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF Piramal Enterprises Limited (IN) 2017-05-31 EP disclosed
WO-2016012965-A2 SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF Piramal Enterprises Limited (IN) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210731-A1 SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF FFAR1, FFAR3, GPR55 FFAR4 12/4885
US-10273230-B2 Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof FFAR1, FFAR3, GPR55 FFAR4 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.